<p>根据公司在最近向美国证券交易委员会提交的 13F 文件，西北互助财富管理公司在 2023 年第四季度将其在西氏医药服务公司（NYSE:WST - 免费报告）的持股增加了 377.4%。该机构投资者在本季度购买了额外的 12,963 股后，持有该医疗器械供应商的 16,398 股股票。截至其最近的 SEC 文件，西北互助财富管理公司在西氏医药服务的持股价值为 4,512,000 美元。</p>
<ul>
<li>3 只有潜力增加股息的股息冠军</li>
</ul>
<p>其他大型投资者最近也调整了对该公司的持股。CYBER HORNET ETFs LLC 在第二季度收购了西氏医药服务的新股份，价值 25,000 美元。Private Trust Co. NA 在第四季度将其在西氏医药服务的持股增加了 156.4%。Private Trust Co. NA 现在持有 100 股该医疗器械供应商的股票，价值 28,000 美元，此前在上个季度又收购了 61 股。国际资产投资管理公司在第四季度收购了西氏医药服务的新股份，价值 31,000 美元。Torren Management LLC 在第四季度收购了西氏医药服务的新股份，价值 34,000 美元。最后，Pilgrim Partners Asia Pte Ltd 在第三季度收购了西氏医药服务的新股份，价值 47,000 美元。机构投资者和对冲基金持有该公司 93.90% 的股票。</p>
<h2>分析师设定新目标价</h2>
<p>WST 最近成为几份研究报告的主题。巴克莱在 2023 年 4 月 27 日的报告中将西氏医药服务的目标价从 275.00 美元上调至 310.00 美元，并给予该公司 “持平” 评级。摩根士丹利在 2023 年 4 月 27 日的报告中设定了 315.00 美元的目标价。德意志银行在 2023 年 2 月 13 日的报告中重申了 “买入” 评级，并设定了 315.00 美元的目标价。Zacks Research 在 2023 年 5 月 13 日的报告中将西氏医药服务的评级从 “持有” 上调至 “强力买入”。最后，花旗集团在 2023 年 4 月 24 日的报告中重申了对西氏医药服务的 “买入” 评级。两位投资分析师给予该股票 “强力买入” 评级，七位给予 “买入” 评级，三位给予 “持有” 评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 322.89 美元。</p>
<ul>
<li>今年将推动标准普尔 500 表现的因素是什么？</li>
</ul>
<p><strong>获取我们关于西氏医药服务的最新研究报告</strong></p>
<h2>西氏医药服务股票上涨 0.2%</h2>
<p>WST 的股票在周五开盘价为 316.86 美元。该公司的市值为 223.9 亿美元，市盈率为 42.36，市盈增长比率为 2.65，贝塔值为 1.17。西氏医药服务公司 12 个月低点为 203.74 美元，12 个月高点为 330.88 美元。该股票的 50 日移动平均价格为 275.46 美元，200 日移动平均价格为 266.35 美元。该公司的流动比率为 2.71，速动比率为 2.04，债务与股本比率为 0.07。</p>
<ul>
<li>至少有 30 年股息增长的医疗保健股票</li>
</ul>
<p>西氏医药服务（NYSE:WST - 获取免费报告）最后一次公布财报是在 2023 年 4 月 23 日。该医疗器械供应商报告本季度每股收益为 2.13 美元，超出市场共识预期的 1.68 美元，超出 0.45 美元。该公司本季度的收入为 8.449 亿美元，而市场共识预期为 7.7968 亿美元。西氏医药服务的股本回报率为 19.03%，净利润率为 16.85%。该公司的季度收入较去年同期增长 21.0%。在去年同期，该公司每股收益为 1.45 美元。西氏医药服务已将其 2026 财年的指导目标设定为每股收益 8.400-8.750 美元，2026 年第二季度的指导目标为每股收益 2.050-2.120 美元。分析师平均预计西氏医药服务公司今年将发布每股收益 8.6 美元。</p>
<p>西氏医药服务宣布其董事会已于 2023 年 2 月 17 日批准了一项股票回购计划，授权公司回购 10 亿美元的流通股。该回购授权允许该医疗器械供应商通过公开市场购买最多 5.6% 的股份。股票回购计划通常表明公司的管理层认为其股票被低估。</p>
<h2>内部活动</h2>
<p>在其他西氏医药服务的新闻中，首席会计官 Chad Winters 在 2023 年 4 月 27 日的交易中出售了 896 股西氏医药服务的股票。该股票以平均价格 300.67 美元出售，总交易额为 269,400.32 美元。交易后，首席会计官直接持有该公司 1,523 股股票，价值约 457,920.41 美元。此次交易使其持股减少了 37.04%。该出售在向证券交易委员会的备案中披露，相关信息可通过此链接访问。此外，副总裁 Annette F. Favorite 在 2023 年 4 月 27 日的交易中出售了 2,817 股西氏医药服务的股票。该股票以平均价格 305.20 美元出售，总价值为 859,748.40 美元。交易后，副总裁直接持有该公司 16,828 股股票，价值 5,135,905.60 美元。此次交易使其持股减少了 14.34%。该出售的 SEC 备案提供了更多信息。目前，内部人士持有该股票的 0.60%。</p>
<h2>关于西氏医药服务</h2>
<p>（免费报告）</p>
<p>西氏医药服务公司是一家全球开发和制造组件、系统及服务的公司，旨在实现可注射药物的封装和输送。该公司专注于为制药和生物技术行业提供高质量的包装和输送解决方案，生产用于疫苗、生物制剂和其他可注射疗法的主要药物包装组件和专用药物输送设备。西氏以其能够保持无菌性和与敏感药物配方兼容的弹性密封件、密封条和聚合物组件而闻名。</p>
<p>除了组件制造，西氏还提供工程化输送系统和产品生命周期支持服务。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过西氏医药服务</li>
<li>Workday 验证了 AI 飞轮：股价恢复开始</li>
<li>HubSpot 在 2019 年水平是一个机会——而不是警告</li>
<li>Decker 的双重超预期是看涨信号——还是仅仅是 HOKA 的把戏？</li>
<li>Kiniksa Pharmaceuticals 在 100% 反弹后仍有上涨空间</li>
</ul>
<p><strong>想知道其他对 WST 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com 获取西氏医药服务公司（NYSE:WST - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在西氏医药服务吗？</h2>
<p>在考虑西氏医药服务之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前立即购买的股票……而西氏医药服务并不在名单上。</p>
<p>虽然西氏医药服务目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

西氏医药服务

2 倍做多纳斯达克生物技术 ETF - ProShares

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 3 倍做多 - Direxion

标普生物技术 ETF - SPDR

生物科技 ETF - VanEck Vectors

纳斯达克生物科技指数 ETF - iShares Nasdaq

医药突破 ETF - ALPS

动态生物技术与基因组 ETF - Invesco

<p>西北互助财富管理公司在第四季度将其在西氏医药服务公司的持股增加了 377.4%，目前持有 16,398 股，价值 450 万美元。其他投资者也调整了他们的持股。分析师设定了新的价格目标，巴克莱将其提高至 310.00 美元。西氏医药的股票开盘价为 316.86 美元，市值为 223.9 亿美元。该公司报告每股收益为 2.13 美元，超出预期，并宣布了一项 10 亿美元的股票回购计划</p>

<p>Northwestern Mutual Wealth Management Co. raised its holdings in West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) by 377.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 16,398 shares of the medical instruments supplier's stock after purchasing an additional 12,963 shares during the quarter. Northwestern Mutual Wealth Management Co.'s holdings in West Pharmaceutical Services were worth $4,512,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>根据公司在最近向美国证券交易委员会提交的 13F 文件，西北互助财富管理公司在 2023 年第四季度将其在西氏医药服务公司（NYSE:WST - 免费报告）的持股增加了 377.4%。该机构投资者在本季度购买了额外的 12,963 股后，持有该医疗器械供应商的 16,398 股股票。截至其最近的 SEC 文件，西北互助财富管理公司在西氏医药服务的持股价值为 4,512,000 美元。</p>
</div><ul>
<li>3 Dividend Champions with room for dividend growth</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只有潜力增加股息的股息冠军</li>
</ul>
</div><p>Other large investors have also recently modified their holdings of the company. CYBER HORNET ETFs LLC acquired a new stake in shares of West Pharmaceutical Services during the 2nd quarter valued at $25,000. Private Trust Co. NA boosted its holdings in shares of West Pharmaceutical Services by 156.4% during the 4th quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier's stock valued at $28,000 after acquiring an additional 61 shares in the last quarter. International Assets Investment Management LLC acquired a new stake in shares of West Pharmaceutical Services during the 4th quarter valued at $31,000. Torren Management LLC acquired a new stake in shares of West Pharmaceutical Services during the 4th quarter valued at $34,000. Finally, Pilgrim Partners Asia Pte Ltd acquired a new stake in shares of West Pharmaceutical Services during the 3rd quarter valued at $47,000. Institutional investors and hedge funds own 93.90% of the company's stock.</p>
<div class="lb-trans"><p>其他大型投资者最近也调整了对该公司的持股。CYBER HORNET ETFs LLC 在第二季度收购了西氏医药服务的新股份，价值 25,000 美元。Private Trust Co. NA 在第四季度将其在西氏医药服务的持股增加了 156.4%。Private Trust Co. NA 现在持有 100 股该医疗器械供应商的股票，价值 28,000 美元，此前在上个季度又收购了 61 股。国际资产投资管理公司在第四季度收购了西氏医药服务的新股份，价值 31,000 美元。Torren Management LLC 在第四季度收购了西氏医药服务的新股份，价值 34,000 美元。最后，Pilgrim Partners Asia Pte Ltd 在第三季度收购了西氏医药服务的新股份，价值 47,000 美元。机构投资者和对冲基金持有该公司 93.90% 的股票。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>WST has been the topic of several recent research reports. Barclays raised their price objective on West Pharmaceutical Services from $275.00 to $310.00 and gave the company an &#34;equal weight&#34; rating in a report on Monday, April 27th. Morgan Stanley set a $315.00 price objective on West Pharmaceutical Services in a report on Monday, April 27th. Deutsche Bank Aktiengesellschaft reissued a &#34;buy&#34; rating and set a $315.00 price objective on shares of West Pharmaceutical Services in a report on Friday, February 13th. Zacks Research raised West Pharmaceutical Services from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a report on Wednesday, May 13th. Finally, Citigroup reissued a &#34;buy&#34; rating on shares of West Pharmaceutical Services in a report on Friday, April 24th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $322.89.</p>
<div class="lb-trans"><p>WST 最近成为几份研究报告的主题。巴克莱在 2023 年 4 月 27 日的报告中将西氏医药服务的目标价从 275.00 美元上调至 310.00 美元，并给予该公司 “持平” 评级。摩根士丹利在 2023 年 4 月 27 日的报告中设定了 315.00 美元的目标价。德意志银行在 2023 年 2 月 13 日的报告中重申了 “买入” 评级，并设定了 315.00 美元的目标价。Zacks Research 在 2023 年 5 月 13 日的报告中将西氏医药服务的评级从 “持有” 上调至 “强力买入”。最后，花旗集团在 2023 年 4 月 24 日的报告中重申了对西氏医药服务的 “买入” 评级。两位投资分析师给予该股票 “强力买入” 评级，七位给予 “买入” 评级，三位给予 “持有” 评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 322.89 美元。</p>
</div><ul>
<li>What Factors Will Drive S&amp;P 500 Performance This Year?</li>
</ul>
<div class="lb-trans"><ul>
<li>今年将推动标准普尔 500 表现的因素是什么？</li>
</ul>
</div><p><strong>Get Our Latest Research Report on West Pharmaceutical Services</strong></p>
<div class="lb-trans"><p><strong>获取我们关于西氏医药服务的最新研究报告</strong></p>
</div><h2>West Pharmaceutical Services Stock Up 0.2%</h2>
<div class="lb-trans"><h2>西氏医药服务股票上涨 0.2%</h2>
</div><p>Shares of WST opened at $316.86 on Friday. The company has a market capitalization of $22.39 billion, a PE ratio of 42.36, a PEG ratio of 2.65 and a beta of 1.17. West Pharmaceutical Services, Inc. has a 12 month low of $203.74 and a 12 month high of $330.88. The stock's 50-day moving average price is $275.46 and its two-hundred day moving average price is $266.35. The company has a current ratio of 2.71, a quick ratio of 2.04 and a debt-to-equity ratio of 0.07.</p>
<div class="lb-trans"><p>WST 的股票在周五开盘价为 316.86 美元。该公司的市值为 223.9 亿美元，市盈率为 42.36，市盈增长比率为 2.65，贝塔值为 1.17。西氏医药服务公司 12 个月低点为 203.74 美元，12 个月高点为 330.88 美元。该股票的 50 日移动平均价格为 275.46 美元，200 日移动平均价格为 266.35 美元。该公司的流动比率为 2.71，速动比率为 2.04，债务与股本比率为 0.07。</p>
</div><ul>
<li>Healthcare Stocks With at Least 30 Years of Dividend Increases</li>
</ul>
<div class="lb-trans"><ul>
<li>至少有 30 年股息增长的医疗保健股票</li>
</ul>
</div><p>West Pharmaceutical Services (NYSE:WST - Get Free Report) last announced its earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 EPS for the quarter, topping the consensus estimate of $1.68 by $0.45. The firm had revenue of $844.90 million for the quarter, compared to the consensus estimate of $779.68 million. West Pharmaceutical Services had a return on equity of 19.03% and a net margin of 16.85%.The business's quarterly revenue was up 21.0% compared to the same quarter last year. During the same period in the previous year, the business earned $1.45 EPS. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. On average, analysts anticipate that West Pharmaceutical Services, Inc. will post 8.6 EPS for the current year.</p>
<div class="lb-trans"><p>西氏医药服务（NYSE:WST - 获取免费报告）最后一次公布财报是在 2023 年 4 月 23 日。该医疗器械供应商报告本季度每股收益为 2.13 美元，超出市场共识预期的 1.68 美元，超出 0.45 美元。该公司本季度的收入为 8.449 亿美元，而市场共识预期为 7.7968 亿美元。西氏医药服务的股本回报率为 19.03%，净利润率为 16.85%。该公司的季度收入较去年同期增长 21.0%。在去年同期，该公司每股收益为 1.45 美元。西氏医药服务已将其 2026 财年的指导目标设定为每股收益 8.400-8.750 美元，2026 年第二季度的指导目标为每股收益 2.050-2.120 美元。分析师平均预计西氏医药服务公司今年将发布每股收益 8.6 美元。</p>
</div><p>West Pharmaceutical Services declared that its Board of Directors has approved a stock buyback program on Tuesday, February 17th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the medical instruments supplier to repurchase up to 5.6% of its shares through open market purchases. Shares buyback programs are generally a sign that the company's management believes its shares are undervalued.</p>
<div class="lb-trans"><p>西氏医药服务宣布其董事会已于 2023 年 2 月 17 日批准了一项股票回购计划，授权公司回购 10 亿美元的流通股。该回购授权允许该医疗器械供应商通过公开市场购买最多 5.6% 的股份。股票回购计划通常表明公司的管理层认为其股票被低估。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In other West Pharmaceutical Services news, CAO Chad Winters sold 896 shares of West Pharmaceutical Services stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $300.67, for a total transaction of $269,400.32. Following the transaction, the chief accounting officer directly owned 1,523 shares of the company's stock, valued at approximately $457,920.41. The trade was a 37.04% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this link. Also, VP Annette F. Favorite sold 2,817 shares of West Pharmaceutical Services stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $305.20, for a total value of $859,748.40. Following the transaction, the vice president directly owned 16,828 shares in the company, valued at $5,135,905.60. The trade was a 14.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.60% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他西氏医药服务的新闻中，首席会计官 Chad Winters 在 2023 年 4 月 27 日的交易中出售了 896 股西氏医药服务的股票。该股票以平均价格 300.67 美元出售，总交易额为 269,400.32 美元。交易后，首席会计官直接持有该公司 1,523 股股票，价值约 457,920.41 美元。此次交易使其持股减少了 37.04%。该出售在向证券交易委员会的备案中披露，相关信息可通过此链接访问。此外，副总裁 Annette F. Favorite 在 2023 年 4 月 27 日的交易中出售了 2,817 股西氏医药服务的股票。该股票以平均价格 305.20 美元出售，总价值为 859,748.40 美元。交易后，副总裁直接持有该公司 16,828 股股票，价值 5,135,905.60 美元。此次交易使其持股减少了 14.34%。该出售的 SEC 备案提供了更多信息。目前，内部人士持有该股票的 0.60%。</p>
</div><h2>About West Pharmaceutical Services</h2>
<div class="lb-trans"><h2>关于西氏医药服务</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.</p>
<div class="lb-trans"><p>西氏医药服务公司是一家全球开发和制造组件、系统及服务的公司，旨在实现可注射药物的封装和输送。该公司专注于为制药和生物技术行业提供高质量的包装和输送解决方案，生产用于疫苗、生物制剂和其他可注射疗法的主要药物包装组件和专用药物输送设备。西氏以其能够保持无菌性和与敏感药物配方兼容的弹性密封件、密封条和聚合物组件而闻名。</p>
</div><p>In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.</p>
<div class="lb-trans"><p>除了组件制造，西氏还提供工程化输送系统和产品生命周期支持服务。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than West Pharmaceutical Services</li>
<li>Workday Validates AI Flywheel: Stock Price Recovery Begins</li>
<li>HubSpot at 2019 Levels Is an Opportunity—Not a Warning</li>
<li>Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?</li>
<li>Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过西氏医药服务</li>
<li>Workday 验证了 AI 飞轮：股价恢复开始</li>
<li>HubSpot 在 2019 年水平是一个机会——而不是警告</li>
<li>Decker 的双重超预期是看涨信号——还是仅仅是 HOKA 的把戏？</li>
<li>Kiniksa Pharmaceuticals 在 100% 反弹后仍有上涨空间</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding WST?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对 WST 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com 获取西氏医药服务公司（NYSE:WST - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=WST"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in West Pharmaceutical Services Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在西氏医药服务吗？</h2>
</div><p>Before you consider West Pharmaceutical Services, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑西氏医药服务之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前立即购买的股票……而西氏医药服务并不在名单上。</p>
</div><p>While West Pharmaceutical Services currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然西氏医药服务目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Northwestern Mutual Wealth Management Co. Has $4.51 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST

Market Beat

巴克莱银行

摩根士丹利

德意志银行

花旗

标普 500 指数

CYBER HORNET S&P500 Bitcoin 75/25StgyETF

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

CITIGROUP INC 6.250 NON CUM SER II PFD WI

西北互助财富管理公司持有西氏医药服务公司价值 451 万美元的股票